The bottom line is there isn't any quality data. But there are a lot of clinical trials in patients going on, so there should be something more reliable in 4 we

The bottom line is there isn't any quality data. But there are a lot of clinical trials in patients going on, so there should be something more reliable in 4 weeks or so. The most relevant endpoint at this time is not viral clearance (which also has reliability issues), it is avoidance of severe disease requiring hospitalisation and respiratory support, in particular invasive ventilation. Also relevant is whether prophylactic treatment in people at high risk of infection, such as healthcare workers, is effective. The treatment courses are short, so the side effects of hydroxychloroquine are largely irrelevant under the circumstances.